Neddylation-activating enzyme inhibitors as viral sensitizers and uses thereof
US-2026015592-A1 · Jan 15, 2026 · US
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · Cooperative Patent Classification (CPC)
Chemical and metallurgical processes, compounds, and materials.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | C12N2750/14134 |
| Official title | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein |
| Display label | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein |
| Total patents | 51 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is declining.
| Year | Patents |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 5 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 11 |
| 2023 | 5 |
| 2024 | 9 |
| 2025 | 4 |
| 2026 | 1 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Immune tolerance induction to viral capsids
US-2025352626-A1 · Nov 20, 2025 · US
Phagemid vector
US-12331308-B2 · Jun 17, 2025 · US
Prostate neoantigens and their uses
US-12295997-B2 · May 13, 2025 · US
Methods of making and using universal centralized influenza vaccine genes
US-2025032601-A1 · Jan 30, 2025 · US
Novel methods of using adeno-associated virus 11 (aav11)
US-2024424085-A1 · Dec 26, 2024 · US
Bocaparvovirus small noncoding rna and uses thereof
US-2024384294-A1 · Nov 21, 2024 · US
Development of a highly efficient second generation fentanyl-conjugate vaccine to treat fentanyl addiction
US-2024307517-A1 · Sep 19, 2024 · US
Replication-competent adenovirus type 4 sars-cov-2 vaccines and their use
US-2024293532-A1 · Sep 5, 2024 · US
Methods of making and using universal centralized influenza vaccine genes
US-12064478-B2 · Aug 20, 2024 · US
Bocaparvovirus small noncoding RNA and uses thereof
US-11999965-B2 · Jun 4, 2024 · US
Or2l13 agonists to treat cvd with dysregulated platelet activation
US-2024108591-A1 · Apr 4, 2024 · US
Composition for immune tolerance induction and use in gene therapy
US-2024082421-A1 · Mar 14, 2024 · US
RAAV with chemically modified capsid
US-11865185-B2 · Jan 9, 2024 · US
Phagemid Vector
US-2023265452-A1 · Aug 24, 2023 · US
Enhancing immune responses through targeted antigen expression
US-2023241203-A1 · Aug 3, 2023 · US
rAAV with chemically modified capsid
US-11648319-B2 · May 16, 2023 · US
Phagemid vector
US-11603540-B2 · Mar 14, 2023 · US
Prostate Neoantigens And Their Uses
US-2023029453-A1 · Feb 2, 2023 · US
Vaccine and method for treating cancer
US-2022370581-A1 · Nov 24, 2022 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC C12N2750/14134?
- CPC C12N2750/14134 is the Cooperative Patent Classification code for “Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein.”
- How many patents are filed under CPC C12N2750/14134 (Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein)?
- Our database includes 51 publications tagged with this CPC code.
- Is patent activity under CPC C12N2750/14134 growing?
- Publication counts under this code: 9 in 2024 vs 4 in 2025 (latest complete years).